Celadon Pharmaceuticals (LSE:CEL) EBIT per Share : €-0.13 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals EBIT per Share?

Celadon Pharmaceuticals's EBIT per Share for the six months ended in Dec. 2023 was €-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Celadon Pharmaceuticals's EBIT per Share or its related term are showing as below:

LSE:CEL's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Celadon Pharmaceuticals's EBIT for the six months ended in Dec. 2023 was €-3.24 Mil.

Celadon Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Celadon Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals EBIT per Share Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.01

-0.61

-0.28

-0.13

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial			-0.37	-0.29	-0.02	-0.08	-0.05

Celadon Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Celadon Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.038	/	61.894
=	-0.13

Celadon Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.235	/	62.118
=	-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.13

Celadon Pharmaceuticals (LSE:CEL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Celadon Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines